表紙:リキッドバイオプシーの世界市場:2021年
市場調査レポート
商品コード
1044144

リキッドバイオプシーの世界市場:2021年

The World Liquid Biopsy Market 2021

出版日: | 発行: Kalorama Information | ページ情報: 英文 228 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
リキッドバイオプシーの世界市場:2021年
出版日: 2021年12月28日
発行: Kalorama Information
ページ情報: 英文 228 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

リキッドバイオプシー検査は、臨床腫瘍学の側面で多くの応用が期待されています。

当レポートでは、世界のリキッドバイオプシー市場について調査し、市場の概要とともに、分析物別、用途別、癌タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

  • イントロダクション
  • リキッドバイオプシー技術
  • 業界構造
  • リキッドバイオプシー市場の収益と予測

第2章 リキッドバイオプシー技術

  • イントロダクション
  • 現在の主要なリキッドバイオプシー技術

第3章 循環腫瘍DNA(CTDNA)リキッドバイオプシー

  • イントロダクション
  • リキッドバイオプシーにおけるCTDNAの利点と制限
  • 現在のCTDNAベースのリキッドバイオプシーテスト
  • 開発中のCTDNAベースのリキッドバイオプシーテスト

第4章 循環腫瘍細胞(CTCS)リキッドバイオプシー

  • イントロダクション
  • CTCベースのリキッドバイオプシーテストの開発における課題
  • CTCベースのリキッドバイオプシーテスト
  • 開発中のCTCベースのリキッドバイオプシーテスト

第5章 細胞外小胞およびその他のリキッドバイオプシー

  • イントロダクション
  • 細胞外小胞/その他の分析物ベースのリキッドバイオプシーテスト
  • 開発中の細胞外小胞/その他の分析物ベースのリキッドバイオプシーテスト

第6章 マルチアナライトリキッドバイオプシーテスト

  • イントロダクション
  • マルチアナライトベースのリキッドバイオプシーテスト
  • 開発中のマルチアナライトベースのリキッドバイオプシーテスト

第7章 調査目的でのみ使用されるリキッドバイオプシーテスト

  • イントロダクション
  • 調査目的でのみ使用されるリキッドバイオプシーテスト

第8章 リキッドバイオプシー業界の分析

  • イントロダクション
  • 競合構造
  • 競合要因
  • 重要な市場動向
  • 個別化医療
  • 世界の平均余命の延伸
  • 新しいリキッドバイオプシー製品
  • 遺伝子検査のアクセシビリティの向上
  • 規制のハードル
  • サードパーティの支払人の補償範囲
  • 実証された臨床的有用性
  • 特定の癌の発生率
  • リキッドバイオプシー市場における競合企業

第9章 リキッドバイオプシー市場

  • 市場概要
  • 市場予測

第10章 分析物別市場

  • 循環腫瘍DNA
  • 循環腫瘍細胞
  • 細胞外小胞およびその他の分析物
  • マルチアナライト

第11章 用途別市場

  • 治療ガイダンスとモニタリング
  • 診断/スクリーニング
  • 疾患の予後

第12章 癌タイプ別市場

  • 乳癌
  • 大腸癌
  • 肺癌
  • 卵巣癌
  • 前立腺癌
  • その他

第13章 リキッドバイオプシー企業のプロファイル

  • リキッドバイオプシー市場の主要企業10社
    • ADAPTIVE BIOTECHNOLOGIES
    • AGENA BIOSCIENCE, INC
    • ANGLE, PLC
    • ASPIRA WOMEN'S HEALTH
    • BIOCARTIS GROUP NV
    • BIOCEPT, INC
    • BIODESIX
    • CELLMAX LIFE
    • CIRCULOGENE
    • DIACARTA, INC
    • EPIC SCIENCES
    • EPIGENOMICS AG
    • EXACT SCIENCES
    • EXOSOME DIAGNOSTICS, INC
    • FOUNDATION MEDICINE, INC(ROCHE)
    • FREENOME, INC
    • GILUPI GMBH
    • GRAIL
    • GUARDANT HEALTH, INC
    • HOLOGIC
    • LUNGLIFE AI
    • MDXHEALTH
    • MENARINI-SILICON BIOSYSTEMS, SPA
    • MYRIAD GENETICS, INC
    • NATERA, INC.
    • NEOGENOMICS LABORATORIES, INC.
    • ONCOCYTE CORPORATION
    • ONCODNA SA
    • ONCIMMUNE
    • PERSONAL GENOME DIAGNOSTICS
    • PREDICINEQ2 SOLUTIONSQIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
    • RESOLUTION BIOSCIENCES(AGILENT)
    • ROCHEDIAGNOSTICS
    • STAGEZERO LIFE SCIENCES
    • SYSMEX-INOSTICS, INC.
    • TEMPUS
    • VERACYTE
    • VOLITIONRX
目次
Product Code: 21-021b

This report, “The World Liquid Biopsy Market, 2021 ”, from Kalorama Information, contains up-to-date information and useful data points for business planning:

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis / screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • LIQUID BIOPSY TECHNOLOGIES
  • INDUSTRY STRUCTURE
  • LIQUID BIOPSY MARKET REVENUES AND FORECAST
    • Figure 1-1: Global Liquid Biopsy Market by Geographic Region, 2021 (%)
    • Table 1-1: Global Liquid Biopsy Market Forecast, by Region ($ millions), 2021-2026
    • Figure 1-2: Global Liquid Biopsy Market Forecast by Region $ millions), 2021-2026

CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES

  • INTRODUCTION
    • Table 2-1: Comparison of Tissue and Liquid Biopsy
  • CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
    • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies

CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY

  • INTRODUCTION
  • ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
  • CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
    • Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2021
  • Biocartis
  • Biocept
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Epigenomics
  • Foundation Medicine (Roche)
  • Guardant Health
  • Inivata (Neogenomics)
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics
  • QIAGEN
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
  • CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • Neogenomics

CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY

  • INTRODUCTION
  • CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
  • CTC-BASED LIQUID BIOPSY TESTS
    • Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Adaptive Biotechnologies
  • Biocept
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2021
  • ANGLE
  • Epic Sciences
  • Liquid Biotech USA

CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES / OTHER ANALYTES
    • Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2021
  • Aspira Women's Health (formerly Vermillion)
  • Biodesix
  • Exosome Diagnostics
  • Hologic
  • MDxHealth
  • EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2021
  • Circulogene
  • OncoCyte
  • Resolution Biosciences
  • VolitionRx

CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES
    • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
  • Biocept
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
  • MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2021
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
    • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2021
  • Agena Bioscience
  • ANGLE
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS

  • INTRODUCTION
  • TIERS OF COMPETITION
    • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2021
  • COMPETITIVE FACTORS
  • SIGNIFICANT MARKET TRENDS
    • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2021
  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
  • COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET
    • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market

CHAPTER 9: LIQUID BIOPSY MARKET

  • MARKET OVERVIEW
    • Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Analyte, 2021 (%)
    • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2021 (%)
    • Figure 9-3: Global Liquid Biopsy Market Estimate by Type of Use, (Research Use, Clinical Diagnostics Use) 2018 (%)
  • MARKET FORECAST
    • Table 9-1: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2021-2026
    • Figure 9-4: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World ( $ millions), 2021-2026

CHAPTER 10: MARKET BY ANALYTE

  • CIRCULATING TUMOR DNA
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2021-2026
  • CIRCULATING TUMOR CELLS
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2021-2026
  • EXTRACELLULAR VESICLES AND OTHER ANALYTES
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2021-2026
  • MULTIPLE ANALYTES
    • Market Overview
    • Revenue Forecast
      • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2018-2023

CHAPTER 11: MARKET BY APPLICATION

  • THERAPY GUIDANCE AND MONITORING
    • Market Overview
    • Revenue Forecast
      • Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2021-2026
  • DIAGNOSIS/SCREENING
    • Market Overview
    • Revenue Forecast
      • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2021-2026
  • DISEASE PROGNOSIS
    • Market Overview
    • Revenue Forecast
      • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2021-2026

CHAPTER 12: MARKET BY CANCER TYPE

  • BREAST CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2021-2026
  • COLORECTAL CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2021-2026
  • LUNG CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2021-2026
  • OVARIAN CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2021-2026
  • PROSTATE CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2021-2026
  • OTHER CANCERS
    • Market Overview
    • Revenue Forecast
      • Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2021-2026

Notes: *Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.

  • PAN-CANCER TESTS
    • Market Overview
    • Revenue Forecast
      • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2021-2026

CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES

  • TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
    • Table 13-1
  • Top Ten Companies in the Liquid Biopsy Market
    • ADAPTIVE BIOTECHNOLOGIES
    • AGENA BIOSCIENCE, INC.
    • ANGLE, PLC
    • ASPIRA WOMEN'S HEALTH
    • BIOCARTIS GROUP NV
    • BIOCEPT, INC.
    • BIODESIX
    • CELLMAX LIFE
    • CIRCULOGENE
    • DIACARTA, INC.
    • EPIC SCIENCES
    • EPIGENOMICS AG
    • EXACT SCIENCES
    • EXOSOME DIAGNOSTICS, INC.
    • FOUNDATION MEDICINE, INC. (ROCHE)
    • FREENOME, INC.
    • GILUPI GMBH
    • GRAIL (ILLUMINA)
    • GUARDANT HEALTH, INC.
    • HOLOGIC
    • LUNGLIFE AI (FORMERLY CYNVENIO BIOSYSTEMS)
    • MDXHEALTH
    • MENARINI-SILICON BIOSYSTEMS, SPA
    • MYRIAD GENETICS, INC.
    • NATERA, INC.
    • NEOGENOMICS LABORATORIES, INC.
    • ONCOCYTE CORPORATION
    • ONCODNA S.A.
    • ONCIMMUNE
    • PERSONAL GENOME DIAGNOSTICS
    • PREDICINEQ2 SOLUTIONSQIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
    • RESOLUTION BIOSCIENCES (AGILENT)
    • ROCHE DIAGNOSTICS
    • STAGEZERO LIFE SCIENCES
    • SYSMEX-INOSTICS, INC.
    • TEMPUS
    • VERACYTE
    • VOLITIONRX